Genetically engineered bacteria could help in Crohn's and colitis

November 2, 2012 by Lin Edwards report

(Medical Xpress)—A new study in mice has shown that genetically engineered bacteria can protect against inflammatory bowel disease (IBD), which includes a host of conditions including ulcerative colitis and Crohn's disease.

IBD conditions are serious ailments in which the gut becomes inflamed and damaged, sometimes so severely that surgery to remove the inflamed sections is the only treatment currently available. The conditions arise when the immune system attacks the gut, for reasons that are poorly understood. Symptoms include cramps, ulcers, weight loss, diarrhea, and the inflammation can result in intestinal scarring and a greater risk of developing .

The study, led by Jean-Paul Motta of the Centre de Physiopathologie de Toulouse Purpan (CPTP) in Toulouse, France, genetically modified two strains of Lactobacillus bacteria by splicing a gene into their DNA that instructs cells to manufacture the naturally-occurring protein, elafin, which the team had noted was deficient in patients with IBD. The bacteria are probiotic and do not cause harm in humans.

Elafin blocks the actions of members of the group of enzymes, which are known to play a role in inflammation. It is expressed in the skin and lungs during healing of trauma. As reported in Phys.org elafin is also now known to be a marker that can be measured by a blood test to determine whether or not skin graft patients will be susceptible to graft-versus-host disease ().

In earlier studies the French and Canadian team of researchers had shown that mice genetically engineered to manufacture more elafin were afforded protection against a condition similar to human colitis. In the new study they aimed to find out if increasing the levels through the use of would also protect against inflammation.

The research team fed the bacteria to mice and found that the levels of elafin increased to greater levels than in fed non-genetically engineered bacteria of the same strains. They induced IBD in the mice and found that those fed the bacteria with the elafin gene had greater resistance, and that there was less inflammation and cell damage. They also reported a reduction in the numbers of neutrophil and macrophage immune cells in the gut.

The researchers also added the bacteria to cultures of gut tissue from human IBD patients and reported that the key signs of were reduced in the presence of the elafin-manufacturing bacteria.

The study findings, reported this week in Science Translational Medicine, suggest that the bacteria could be of benefit to IBD patients, and could be given in pill form or alternatively, the food-grade bacteria could be added as live cultures to yogurts. More research is needed to ensure the best strains of bacteria are selected and to ensure the safety and efficacy of the treatment in human patients.

Explore further: Study furthers understanding of IBD

More information: Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis, Sci Transl Med 31 October 2012: Vol. 4, Issue 158, p. 158ra144 DOI: 10.1126/scitranslmed.3004212

ABSTRACT
Elafin, a natural protease inhibitor expressed in healthy intestinal mucosa, has pleiotropic anti-inflammatory properties in vitro and in animal models. We found that mucosal expression of Elafin is diminished in patients with inflammatory bowel disease (IBD). This defect is associated with increased elastolytic activity (elastase-like proteolysis) in colon tissue. We engineered two food-grade strains of lactic acid bacteria (LAB) to express and deliver Elafin to the site of inflammation in the colon to assess the potential therapeutic benefits of the Elafin-expressing LAB. In mouse models of acute and chronic colitis, oral administration of Elafin-expressing LAB decreased elastolytic activity and inflammation and restored intestinal homeostasis. Furthermore, when cultures of human intestinal epithelial cells were treated with LAB secreting Elafin, the inflamed epithelium was protected from increased intestinal permeability and from the release of cytokines and chemokines, both of which are characteristic of intestinal dysfunction associated with IBD. Together, these results suggest that oral delivery of LAB secreting Elafin may be useful for treating IBD in humans.

Related Stories

Study furthers understanding of IBD

October 12, 2012
Researchers part-funded by the Medical Research Council (MRC) and the Wellcome Trust have identified how particular parts of the intestinal immune system and the bacteria in the gut can interact to alter an individual's risk ...

Bacteria-immune system 'fight' can lead to chronic diseases, study suggests

August 2, 2012
Results from a study conducted at Georgia State University suggest that a "fight" between bacteria normally living in the intestines and the immune system, kicked off by another type of bacteria, may be linked to two types ...

Immune system compensates for 'leaky gut' in inflammatory bowel disease susceptibility

September 13, 2012
New research could clarify how inflammatory bowel diseases (IBD), conditions that include ulcerative colitis and Crohn's disease, are triggered and develop.

Could a probiotic be used to treat inflammatory bowel disease?

October 20, 2011
Scientists have been unclear for some time about how most probiotics work. A new study has found a scientific 'design' for a probiotic that could be used to treat inflammatory bowel disease (IBD), such as Crohn's disease.

Recommended for you

Synthetic hydrogels deliver cells to repair intestinal injuries

October 23, 2017
By combining engineered polymeric materials known as hydrogels with complex intestinal tissue known as organoids - made from human pluripotent stem cells - researchers have taken an important step toward creating a new technology ...

Study reveals connection between microbiome and autoimmune disorders

October 23, 2017
Many people associate the word "bacteria" with something dirty and disgusting. Dr. Pere Santamaria disagrees. Called the microbiome, the bacteria in our bodies have all kinds of positive effects on our health, Santamaria ...

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.